An innovative research effort has found that delivering regenerative cells to developing infants diagnosed with spina bifida as part of a surgical repair could constitute a "important advancement" in treating birth defects.
Research Framework and Assurance
The research conducted in the United States focused on six unborn babies with the 'open' form of spina bifida. Doctors administered placenta-derived mesenchymal stem cells to the surface of the baby's spinal cord as part of the surgical correction.
Significantly, the stem cell application was found to be safe. Doctors verified that the cells did not cause neoplasms, disrupt the healing process, or impede the resolution of co-occurring hindbrain herniation.
Encouraging Results
Magnetic resonance imaging performed on the newborns showed a complete reversal of hindbrain herniation in each of the babies. This brain structure normalization is a key indicator for improved motor skills and quality of life.
"In the event it allows additional babies to achieve ambulation who otherwise would not, it could establish itself as their standard of care," said the lead researcher. "These findings are profoundly encouraging and open the door to lots of potential new treatments."
Broader Impact and Encouragement
Experts not involved in the trial indicated that further confirmation of these apparent benefits could herald a "different age" in in-utero treatment. The prospect of enhancing neurological damage present before birth is considered a transformative goal.
Notably important would be improvements in bladder and bowel function, which are frequent complications for those diagnosed with this defect.
Future Directions
Although this preliminary study was small in scale, its established security and encouraging indicators provide a strong foundation for larger, more comprehensive studies. The integration of stem cell therapy with established fetal surgery techniques holds considerable promise for improving the prognosis for infants diagnosed prenatally with spina bifida.